Agilent Technologies Reports 10% Revenue Increase in Recent 10-Q

By Philip Seaworth • Tuesday, September 02 06:02 • Permanent Link

Agilent Technologies, Inc. has recently released its 10-Q report, providing insights into its financial performance and operations. The company, incorporated in 1999 and headquartered in Santa Clara, California, operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. These segments offer a wide range of solutions and services to the life sciences, diagnostics, and applied chemical markets globally.

In the 10-Q report, Agilent Technologies, Inc. reported net revenue of $1,738 million and $5,087 million for the three and nine months ended July 31, 2025, marking a 10 percent and 6 percent increase, respectively, compared to the same periods last year. The company's segments, geographic regions, and key end markets all contributed to this revenue growth. Additionally, the net income for the three and nine months ended July 31, 2025, was $336 million and $869 million, respectively, compared to net income of $282 million and $938 million for the corresponding periods last year.

During the same periods, Agilent Technologies, Inc. paid cash dividends of $0.248 per common share or $71 million and $0.744 per common share or $212 million, respectively, on the company's common stock. Furthermore, the company repurchased and retired 737,474 shares for $85 million and 2.734 million shares for $340 million, excluding excise taxes, during the three and nine months ended July 31, 2025, respectively, under its share repurchase program.

The report also highlighted the company's restructuring plans, including a restructuring plan announced in fiscal year 2025 to optimize its management structure. The restructuring activities are estimated to result in a reduction of approximately $75 million to $80 million in annual cost of sales and operating expenses over the three business segments. As of July 31, 2025, the aggregate restructuring liability was $23 million, recorded in other accrued liabilities on the condensed consolidated balance sheet.

Today the company's shares have moved 0.56% to a price of $125.66. Check out the company's full 10-Q submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.